ArticleBMC medicine2017
Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility.
Article in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 79 citations in OpenAlex.
- Review
- Seminal-Plasma Molecular Biomarkers as a Liquid Biopsy of Testicular Function: Toward AI-Ready Sperm-Retrieval Prediction in Non-Obstructive Azoospermia.International journal of molecular sciences · 2026Review
- Proteomic signatures of sperm and extracellular vesicles associated with sperm freezability in Holstein bulls.Scientific reports · 2026Article
- Opportunities and Challenges of Multiomics for Discovery and Monitoring of Human Pathogens.Environment & health (Washington, D.C.) · 2025Review
- Andrology laboratory technique for analysis of semen in men with azoospermia.Asian journal of andrology · 2025Review
- Differentiation between nonobstructive azoospermia and obstructive azoospermia: then and now.Asian journal of andrology · 2025Review
- Developing a nomogram model for predicting non-obstructive azoospermia using machine learning techniques.Scientific reports · 2025Article
- Associations between seminal plasma osteopontin level and sperm motility in infertile men with asthenozoospermia.Frontiers in endocrinology · 2025Article
- Bringing proteomics to bear on male fertility: key lessons.Expert review of proteomics · 2024Review
- Proteomic biomarkers in seminal plasma as predictors of reproductive potential in azoospermic men.Frontiers in endocrinology · 2024Article
- Non-invasive biomarkers for sperm retrieval in non-obstructive patients: a comprehensive review.Frontiers in endocrinology · 2024Review
- Redefining serological diagnostics with immunoaffinity proteomics.Clinical proteomics · 2023Review
- Non-Invasive Diagnostics of Male Spermatogenesis from Seminal Plasma: Seminal Proteins.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Seminal plasma biomarkers for predicting successful sperm retrieval in patients with nonobstructive azoospermia: a narrative review of human studies.Basic and clinical andrology · 2023Review
- Mass Spectrometry-Based Untargeted Approaches to Reveal Diagnostic Signatures of Male Infertility in Seminal Plasma: A New Laboratory Perspective for the Clinical Management of Infertility?International journal of molecular sciences · 2023Review
- Sertoli cell-only syndrome: advances, challenges, and perspectives in genetics and mechanisms.Cellular and molecular life sciences : CMLS · 2023Review
- New horizons in human sperm selection for assisted reproduction.Frontiers in endocrinology · 2023Review
- Rational Design and Development of SARS-CoV-2 Serological Diagnostics by Immunoprecipitation-Targeted Proteomics.Analytical chemistry · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundTEX101 is a cell membrane protein exclusively expressed by testicular germ cells and shed into seminal plasma. We previously verified human TEX101 as a biomarker for the differential diagnosis of azoospermia, and developed a first-of-its-kind TEX101 ELISA. To demonstrate the clinical utility of TEX101, in this work we aimed at evaluating ELISA performance in a large population of fertile, subfertile, and infertile men.
methodsMass spectrometry, size-exclusion chromatography, ultracentrifugation, and immunohistochemistry were used to characterize TEX101 protein as an analyte in seminal plasma. Using the optimized protocol for seminal plasma pretreatment, TEX101 was measured by ELISA in 805 seminal plasma samples.
resultsWe demonstrated that TEX101 was present in seminal plasma mostly in a free soluble form and that its small fraction was associated with seminal microvesicles. TEX101 median values were estimated in healthy, fertile pre-vasectomy men (5436 ng/mL, N = 64) and in patients with unexplained infertility (4967 ng/mL, N = 277), oligospermia (450 ng/mL, N = 270), and azoospermia (0.5 ng/mL, N = 137). Fertile post-vasectomy men (N = 57) and patients with Sertoli cell-only syndrome (N = 13) and obstructive azoospermia (N = 36) had undetectable levels of TEX101 (≤0.5 ng/mL). A cut-off value of 0.9 ng/mL provided 100% sensitivity at 100% specificity for distinguishing pre- and post-vasectomy men. The combination of a concentration of TEX101 > 0.9 ng/mL and epididymis-specific protein ECM1 > 2.3 μg/mL provided 81% sensitivity at 100% specificity for differentiating between non-obstructive and obstructive azoospermia, thus eliminating the majority of diagnostic testicular biopsies. In addition, a cut-off value of ≥0.6 ng/mL provided 73% sensitivity at 64% specificity for predicting sperm or spermatid retrieval in patients with non-obstructive azoospermia.
conclusionsWe demonstrated the clinical utility of TEX101 ELISA as a test to evaluate vasectomy success, to stratify azoospermia forms, and to better select patients for sperm retrieval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.